New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 7, 2002, Pages 919-923

  Ageno, Walter ^a   Turpie, Alexander G G ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATORVASTATIN; DALTEPARIN; ENALAPRIL; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OMEPRAZOLE; TINZAPARIN;

ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE; CASE REPORT; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; ELECTROCARDIOGRAM; EMERGENCY WARD; HEALTH CARE MANAGEMENT; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MALE; ONSET AGE; PATIENT CARE; PEPTIC ULCER; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STENOSIS; THORAX PAIN;

EID: 0036211837     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Unstable angina: New insights into pathophysiologic characteristics, prognosis and management strategies
2. Pathogenesis of thrombosis in unstable angina
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
4. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes
5. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
6. Diagnosing and managing unstable angina
7. Heparin
8. Low-molecular-weight heparins
9. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation
10. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
11. Low-molecular-weight heparin during instability in coronary artery disease
12. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
13. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris
14. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC)
15. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
17. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events
18. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
19. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events
20. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
21. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
22. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S (FRAxiparine in Ischaemic Syndrome)
23. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
24. Management of unstable angina and myocardial infarction
25. Guidelines for the early management of acute coronary syndromes: Focus on antithrombotic and antiplatelet therapy